与使用闭环胰岛素治疗的标准胰岛素lispro和aspart相比,超快速作用的lispro或快速作用的aspart:随机对照试验的系统审查和元分析
Mohamed Saad Rakab1, Rahma Mogahed Rateb2, Basel Hatem Elsalakawi1
1Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Frontiers in endocrinology
|June 23, 2025
概括
超快速作用胰岛素 (URAI) 与混合闭环 (HCL) 系统相结合,有望降低葡萄糖变化和低血糖风险. 需要进一步的研究来证实对整体血糖控制的益处.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 超快速作用胰岛素 (URAI) 通过尽量减少可变性,为改善血糖控制提供了潜力.
- 在混合闭环 (HCL) 胰岛素输送系统中使用URAI的最佳策略需要进一步研究.
研究的目的:
- 评估将URAI与HCL系统相结合的疗效和安全性.
- 评估对维持euglycemic范围和减少血糖外游的影响.
主要方法:
- 在主要数据库 (PubMed,Scopus,Cochrane,Web of Science) 进行系统的文献搜索.
- 包括在HCL系统中评估URAI的研究,分析范围内的时间 (TIR),范围以下的时间 (TBR),范围以上的时间 (TAR) 和不良事件.
- 对二分制 (风险比率) 和连续 (平均差异) 结果的元分析,具有95%的置信区间.
主要成果:
- URAI显示了向改善TIR (70-180 mg/dL) 的非显著趋势.
- 随着URAI-HCL的使用,血糖变化 (变化系数,P=0.02) 和低血糖 (TBR <70 mg/dL,P=0.002) 的显著降低被观察到.
- 没有发现超出范围的时间显著减少 (>180 mg/dL或>250 mg/dL).
结论:
- 将URAI与HCL系统相结合显示出增强血糖控制的潜力,特别是在减少可变性和低血糖方面.
- 需要进行更大规模的研究来验证这些发现,并为HCL治疗中URAI的临床实践指南提供信息.
相关概念视频
Insulin Formulations: Types and Delivery
277
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
277
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Insulin: Dosing Regimen and Adverse Effects
270
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
270
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Insulin: Biosynthesis, Chemistry, and Preparation
569
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
569
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271


